Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹1,23,206 Cr
P/E Ratio
24.69
P/B Ratio
4.11
Industry P/E
37.25
Debt to Equity
0.01
ROE
16.63 %
ROCE
22.77 %
Div. Yield
0.85 %
Book Value
370.78
EPS
61.79
CFO
₹25,971.01 Cr
EBITDA
₹36,263.61 Cr
Net Profit
₹20,119.58 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Cipla
| -0.20 | 0.12 | 8.11 | 9.13 | 16.42 | 20.55 | 9.12 |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
BSE Healthcare
| -7.27 | -1.01 | -0.76 | 19.87 | 19.29 | 22.12 | 9.77 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Cipla
| 22.22 | 15.83 | 13.97 | 14.21 | 72.29 | -8.57 | -15.04 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 1,174.80 | 97,927.51 | 18.23 | 18.21 | |
| 2,557.50 | 1,05,275.60 | 51.57 | 20.49 | |
| 1,787.40 | 4,28,725.17 | 37.5 | 17.76 | |
| 3,238.90 | 1,09,519.25 | 58.82 | 25.93 |
2 min read•By Mohammed Ekramul Haque
Challenge the equity-return assumption
6 min read•By Aarati Krishnan
FIIs Vs DIIs: Different strokes
3 min read•By Kumar Shankar Roy
2 min read•By Mohammed Ekramul Haque
2 min read•By Mohammed Ekramul Haque and Vikas Vardhan
Five stocks poised for take-off
1 min read•By Mohammed Ekramul Haque and Vikas Vardhan
Cipla Limited, together with its subsidiaries, manufactures, develops, and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New ventures segments. It also... offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. In addition, the company provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Further, it offers Easylax and Easylax L, a liquid paraffin for constipation. Cipla Limited was incorporated in 1935 and is based in Mumbai, India. Read more
Incorporated
1935
Chairman
Y K Hamied
Managing Director
Umang Vohra
Group
Cipla
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Cipla Ltd stood at ₹ 34,655 Cr as on 31-Dec-24
The share price of Cipla Ltd is ₹1,525.90 (NSE) and ₹1,525.50 (BSE) as of 25-Apr-2025 IST. Cipla Ltd has given a return of 16.42% in the last 3 years.
Cipla Ltd has a market capitalisation of ₹ 1,23,206 Cr as on 25-Apr-2025. As per Value Research classification, it is a Large Cap company.
The P/B ratio of Cipla Ltd is 4.11 times as on 25-Apr-2025, a 20% discount to its peers’ median range of 5.15 times.
The P/E ratio of Cipla Ltd is 24.69 times as on 25-Apr-2025, a 34% discount to its peers’ median range of 37.25 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Cipla Ltd and enter the required number of quantities and click on buy to purchase the shares of Cipla Ltd.
Cipla Limited, together with its subsidiaries, manufactures, develops, and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New ventures segments. It also offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. In addition, the company provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Further, it offers Easylax and Easylax L, a liquid paraffin for constipation. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.
The prominent promoters of Cipla Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
Yusuf Khwaja Hameid |
18.68%
|
|
SOPHIE AHMED |
5.71%
|
|
M K HAMIED |
3.46%
|
The chairman of the company is Y K Hamied, and the managing director is Umang Vohra.
There is no promoter pledging in Cipla Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
4,28,725
|
|
|
1,09,519
|
|
|
1,05,276
|
|
|
97,928
|
| Cipla Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
18.12
|
|
Operating margin(%)
|
21.57
|
|
Net Margin(%)
|
17.99
|
|
Dividend yield(%)
|
0.85
|
Yes, TTM profit after tax of Cipla Ltd was ₹4,990 Cr.
₹-25.80
(
